Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.76 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22058844 | 1.00 | GAA (0.76) | GAAOPRM1OPRD1OPRK1KDM4E | |
| SCHEMBL10222579 | 1.00 | GAA (0.76) | GAAOPRM1OPRD1OPRK1KDM4E | |
| SCHEMBL17284763 | 0.96 | GAA (0.73) | GAAOPRM1OPRD1OPRK1KDM4E | |
| SCHEMBL12960788 | 0.96 | GAA (0.73) | GAAOPRM1OPRD1OPRK1KDM4E | |
| SCHEMBL12646380 | 0.96 | GAA (0.73) | GAAOPRM1OPRD1OPRK1KDM4E | |
| SCHEMBL18473577 | 0.96 | GAA (0.73) | GAAOPRM1OPRD1OPRK1KDM4E | |
| SCHEMBL21202057 | 0.88 | GAA (0.75) | GAAOPRM1OPRD1OPRK1KDM4E | |
| SCHEMBL22058796 | 0.88 | GAA (0.75) | GAAOPRM1OPRD1OPRK1KDM4E | |
| SCHEMBL10223930 | 0.88 | GAA (0.75) | GAAOPRM1OPRD1OPRK1KDM4E | |
| SCHEMBL11176847 | 0.88 | OPRM1 (0.60) | GAAOPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11142502-B2 | (+)-morphinans as antagonists of Toll-like receptor 9 and therapeutic uses thereof | MALLINCKRODT LLC (US) | 2021-10-12 | — | — | US | disclosed |
| US-20200172488-A1 | (+)-MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF | MALLINCKRODT LLC | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11142502-B2 | (+)-morphinans as antagonists of Toll-like receptor 9 and therapeutic uses thereof | TLR9, TLR3, TLR7 | GAA 1100/4885OPRM1 5/4885OPRD1 13/4885 |
| US-20200172488-A1 | (+)-MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF | TLR9, TLR3, TLR7 | GAA 1100/4885OPRM1 5/4885OPRD1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.